Dirk Arnold
#135,980
Most Influential Person Now
Researcher
Dirk Arnold's AcademicInfluence.com Rankings
Dirk Arnoldcomputer-science Degrees
Computer Science
#6233
World Rank
#6574
Historical Rank
Machine Learning
#1953
World Rank
#1979
Historical Rank
Artificial Intelligence
#2201
World Rank
#2239
Historical Rank
Database
#3334
World Rank
#3475
Historical Rank
Download Badge
Computer Science
Dirk Arnold's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Dirk Arnold Influential?
(Suggest an Edit or Addition)Dirk Arnold's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012) (1300)
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (2019) (1152)
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. (2013) (980)
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) (971)
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (947)
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2022) (908)
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (789)
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2016) (780)
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017) (577)
- Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. (2012) (562)
- Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. (2015) (512)
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (483)
- Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. (2014) (392)
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2016) (390)
- Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS (2018) (370)
- Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) (312)
- [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. (2011) (287)
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (282)
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (281)
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (268)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (263)
- S3-Leitlinie „Kolorektales Karzinom”– Aktualisierung 2008 (2008) (253)
- Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial (2017) (236)
- Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. (2006) (214)
- Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. (2009) (211)
- Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. (2015) (195)
- Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (192)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (185)
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (174)
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group (2016) (172)
- Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. (2014) (172)
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial (2015) (166)
- Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. (2008) (159)
- Skeletal muscle metastases: primary tumours, prevalence, and radiological features (2010) (157)
- Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. (2008) (156)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (142)
- Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020 (2020) (131)
- Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. (2013) (130)
- Anti-angiogenic therapies for metastatic colorectal cancer. (2009) (120)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (117)
- S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). (2010) (104)
- Corrections to "Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (102)
- Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
- Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative (2015) (101)
- [Update S3-guideline "colorectal cancer" 2008]. (2008) (101)
- Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. (2012) (99)
- Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma (2000) (99)
- Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. (2013) (93)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (87)
- Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies. (2017) (84)
- Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. (2018) (83)
- A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis (2007) (83)
- Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (81)
- Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab (2017) (81)
- Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. (2016) (80)
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial (2014) (79)
- Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749) (2014) (77)
- Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group (2008) (76)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (76)
- Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (75)
- Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. (2014) (72)
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study (2019) (68)
- Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study (2010) (67)
- Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. (2013) (64)
- Oxaliplatin: a review of approved uses (2012) (62)
- Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials (2010) (61)
- S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL (2019) (60)
- International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. (2020) (59)
- Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy (2018) (59)
- Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. (2010) (58)
- Targeted treatments in colorectal cancer: state of the art and future perspectives (2010) (57)
- Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (2011) (56)
- Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) (2008) (55)
- Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. (2012) (54)
- Methylated free‐circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer (2017) (53)
- EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients (2011) (52)
- Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review (2018) (52)
- Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. (2021) (52)
- Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. (2008) (51)
- A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. (2000) (51)
- ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. (2017) (51)
- Review article: panitumumab ‐ a fully human anti‐EGFR monoclonal antibody for treatment of metastatic colorectal cancer (2008) (48)
- Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer : the AIO-FLOT 3 trial (2017) (48)
- A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial (2013) (46)
- Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey (2018) (46)
- Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. (2012) (44)
- Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. (2011) (42)
- Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial (2005) (41)
- Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (40)
- Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie (2013) (40)
- Targeted therapy for metastatic colorectal cancer (2018) (40)
- A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results (2005) (39)
- Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper (2020) (39)
- Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice (2010) (39)
- Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer (2013) (38)
- Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. (2020) (38)
- Central Venous Catheter Complications during Home Parenteral Nutrition: A Prospective Pilot Study of 481 Patients with More than 30,000 Catheter Days (2008) (36)
- Update on capecitabine in colorectal cancer. (2006) (35)
- Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial (2018) (34)
- Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. (2009) (34)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (34)
- The role of gemcitabine alone and in combination in the treatment of pancreatic cancer (2000) (34)
- Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. (2006) (33)
- Induction Chemotherapy before Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer (2010) (32)
- Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial (2009) (32)
- Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study) (2012) (31)
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. (2019) (31)
- Report on the status of women occupying leadership roles in oncology (2018) (30)
- When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab. (2009) (30)
- Prevalence and patterns of renal involvement in imaging of malignant lymphoproliferative diseases (2012) (30)
- Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT) (2020) (29)
- Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (2018) (27)
- Intramuscular manifestation of non-hodgkin lymphoma and myeloma: Prevalence, clinical signs, and computed tomography features (2010) (26)
- Port Catheter Insufficiency: Incidence and Clinical-Radiological Correlations (2008) (25)
- Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature (2012) (24)
- Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2012) (23)
- Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. (2013) (23)
- New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy (2013) (21)
- Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. (2016) (21)
- Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib (2019) (21)
- Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. (2016) (21)
- MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach (2018) (20)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. (2021) (20)
- Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study (2014) (20)
- PTEN deletion is rare but often homogeneous in gastric cancer (2012) (19)
- A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer (2014) (19)
- Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions (2018) (19)
- Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. (2018) (18)
- Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. (2015) (18)
- Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial (2018) (18)
- A Randomised Phase II Study of Irinotecan in Combination with 5-FU/FA Compared with Irinotecan Alone as Second-Line Treatment of Patients with Metastatic Colorectal Carcinoma (2007) (18)
- Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO‐04 randomized phase 3 rectal cancer trial (2019) (17)
- Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study (2015) (17)
- LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy (2020) (17)
- Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results (2014) (17)
- Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO) (2006) (17)
- Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2022) (17)
- Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer (2010) (16)
- Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. (2019) (16)
- [Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer]. (2012) (16)
- Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group (2007) (16)
- Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013 (2014) (15)
- Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108. (2016) (15)
- Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205 (2013) (15)
- The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study (2014) (15)
- Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. (2009) (15)
- Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events (2015) (14)
- Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study (2015) (14)
- Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group (2012) (14)
- (Neo-)adjuvant treatments in colorectal cancer. (2005) (13)
- Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer (2018) (13)
- The role of biological agents in the resection of colorectal liver metastases. (2012) (13)
- Maximising clinical benefit with adequate patient management beyond the second line in mCRC (2019) (13)
- Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
- InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease. (2015) (12)
- Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). (2018) (12)
- Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study (2016) (12)
- Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial (2018) (12)
- The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis (2020) (12)
- Preclinical Evaluation of ZD1839 Alone or in Combination with Oxaliplatin in a Panel of Human Tumor Cell Lines – Implications for Clinical Use (2005) (11)
- Clinical outcome, risk assessment, and seasonal variation in hospitalized COVID-19 patients—Results from the CORONA Germany study (2021) (11)
- Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy (2005) (11)
- Breast plasmacytoma (2010) (11)
- Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. (2019) (11)
- Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction (2013) (10)
- Challenges in the multidisciplinary management of stage IV colon and rectal cancer (2015) (10)
- Oxaliplatin added to fl uorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer ( the German CAO / ARO / AIO-04 study ) : fi nal results of the multicentre , open-label , randomised , phase 3 trial (2019) (10)
- Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France (2020) (10)
- Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd- and/or 3rd-line treatment in patients with metastatic colorectal cancer (2005) (10)
- Personalized Treatment of Colorectal Cancer (2012) (10)
- Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials (2017) (9)
- Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer (2002) (9)
- Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study (2016) (9)
- 612TiPMODUL-A MULTICENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN THERAPY FOR THE 1ST-LINE MAINTENANCE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A SIGNAL-SEEKING APPROACH. (2014) (9)
- Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. (2011) (9)
- A prospective trial for defining a subset of patients with limited metastatic gastric cancer who may be candidates for bimodal treatment strategies: FLOT3. (2012) (9)
- Critical evaluation of the scientific content in clinical practice guidelines (2015) (8)
- The integration of targeted agents into systemic therapy of metastatic colorectal cancer. (2006) (8)
- Therapiefolgen bei Krebs-Langzeitüberlebenden (2012) (8)
- Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. (2021) (8)
- Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) vs. capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI study group (2007) (8)
- Bratislava Statement: consensus recommendations for improving pancreatic cancer care (2020) (7)
- First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group (2011) (7)
- Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer (2008) (7)
- Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. (2021) (7)
- The Oncology Data Network (ODN): A Collaborative European Data‐Sharing Platform to Inform Cancer Care (2019) (7)
- Analysis of Bevacizumab-based Preoperative Radiochemotherapy in Patients with Locally Advanced Rectal Cancer on Surgery-associated Spectrum of Complications (2014) (7)
- IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703. (2015) (7)
- Clinical Management of Localized Colon Cancer with Capecitabine (2012) (7)
- Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor (2016) (7)
- Gastrointestinale Tumore – interdisziplinäre Diskussion neuer Daten (2011) (7)
- COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) (2022) (7)
- Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First‐line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial (2018) (7)
- Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform. (2015) (7)
- Phase II study of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma. (1985) (7)
- Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival. (2015) (7)
- O-0021 Randomised Phase III Study of Bevacizumab + Chemotherapy Beyond Progression in Bevacizumab-Treated Patients with Metastatic Colorectal Cancer: TML Study Kras Subgroup Findings (2012) (6)
- Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study (2020) (6)
- Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study (2010) (6)
- Activity of mTOR-Inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines. (2009) (6)
- Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer (2014) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015 (2016) (6)
- Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2011) (6)
- Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis (2018) (6)
- Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study (2012) (6)
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial (2015) (6)
- Phase I/II study of cetuximab, capecitabine and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC). (2006) (6)
- Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): Combined analysis of two randomized first-line phase II trials of the AIO CRC study group (2008) (6)
- Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. (2012) (5)
- Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer (2017) (5)
- Spezielle Therapiesituationen beim metastasierten kolorektalen Karzinom (2010) (5)
- Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147) (2012) (5)
- The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer (2020) (5)
- Complete Remission in a Colon Cancer Patient with a Large, Irresectable Liver Metastasis after XELOX/Cetuximab/Bevacizumab Treatment (2008) (5)
- Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature (2016) (5)
- Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. (2019) (5)
- Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. (2020) (5)
- Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts. (2020) (5)
- A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer (2022) (5)
- Cetuximab, capecitabine, and oxaliplatin (Cet-CapOx) with concurrent radiotherapy (RT) in advanced rectal cancer (RC): Results of a phase I/II trial (2007) (5)
- Phase I trial of docetaxel, oxaliplatin and capecitabine (TEX) in patients with metastatic gastric cancer. (2006) (5)
- Anti-angiogenic therapies for metastatic colorectal cancer (Review) (2009) (5)
- Bevacizumab (BV) plus chemotherapy (CT) as first-line treatment of patients with metastatic colorectal cancer (mCRC): First results from a large community-based observational cohort study in Germany. (2016) (4)
- Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC). (2018) (4)
- Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: Interim results from a phase II trial by the German AIO Group. (2016) (4)
- Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. (2021) (4)
- [Adjuvant therapy in colon cancer]. (2010) (4)
- Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. (2020) (4)
- Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. (2021) (4)
- Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients—Results from the CORONA Germany Study (2021) (4)
- Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): A pooled analysis of randomized phase II-III trials (2008) (4)
- Localization of the primary tumor (LPT) and maintenance strategies after first line oxaliplatin (Ox), fluoropyrimidine (FP), and bevacizumab (Bev) in metastatic colorectal cancer (mCRC): Results from the AIO 0207 trial. (2017) (4)
- The ESMO guideline strategy: an identity statement and reflections on improvement. (2015) (4)
- Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2011) (4)
- [Palliative treatment for colorectal cancer]. (2009) (4)
- Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2017) (3)
- A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL. (2020) (3)
- 147 : Cetuximab in Combination With Capecitabine, Oxaliplatin and Concomitant Radiotherapy (Cet-Capox-RT) as Preoperative Therapy for Rectal Cancer (2006) (3)
- The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression ≥ 9 months (mos) versus < 9 mos. (2014) (3)
- A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703. (2015) (3)
- Auf dem Weg zum «Single-Regulator»? Medienregulierung in Europa. (2013) (3)
- Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer. (2010) (3)
- The role of peri-operative treatment in resectable liver metastases of colorectal cancer (2010) (3)
- ASCO-Update 2015 – Neuigkeiten vom 51. Meeting der American Society of Clinical Oncology/ASCO 2015 (2004) (3)
- Verbraucherschutz im Internet. Anforderungen an die Umsetzung der Fernabsatz-Richtlinie (1997) (3)
- Studien und personalisierte Medizin in der Onkologie? (2010) (3)
- The Oncology Data Network (ODN): Methodology, Challenges and Achievements. (2020) (3)
- Multimodality treatment of colorectal peritoneal metastasis with perioperative systemic chemotherapy, cytoreductive surgery (CRS), and HIPEC: First safety results of the COMBATAC trial. (2014) (3)
- Anti-angiogenic therapy for metastatic colorectal cancer (2007) (3)
- Associations between the EGFR status as well as KRAS mutations and clinical outcome in colorectal cancer (CRC) patients (pts) treated with erlotinib monotherapy in 2nd or 3rd line—A study of the Arbeitsgemeinschaft Internistische (2008) (3)
- Use of EGF a+61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery. (2010) (3)
- Continuation of regional chemotherapy of hepatic neoplasms despite occlusion of the hepatic artery—report of four cases (2002) (3)
- Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147. (2013) (3)
- Chemotherapy in rectal cancer (2005) (3)
- A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas. (2004) (3)
- A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas (2004) (3)
- Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital (2022) (3)
- The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study. (2011) (2)
- Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial (2016) (2)
- Anti-angiogenic therapies for metastatic colorectal cancer (MCRC): Preliminary results of a systematic review and meta-analysis (2008) (2)
- Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). (2022) (2)
- Multimodale Therapiestrategien bei Lebermetastasen kolorektaler Karzinome (2011) (2)
- BECAM: A salvage protocol with bevacizumab, capecitabin, and mitomycin C for patients with refractory metastatic colorectal cancer (CRC) or gastric cancer (GC). (2006) (2)
- Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205. (2011) (2)
- Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer. (2021) (2)
- Treating Gastrointestinal Cancer During the Coronavirus Disease 2019 Pandemic in Europe (2020) (2)
- [Systemic treatment of peritoneal metastases]. (2007) (2)
- 522PQUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING MAINTENANCE THERAPY AFTER FIRST-LINE INDUCTIVE TREATMENT: A QOL SUB-ANALYSIS OF THE AIO KRK 0207 PHASE III TRIAL. (2014) (2)
- Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group (2021) (2)
- [Clinical trials and personalized medicine in oncology?]. (2010) (2)
- Diagnostik und Therapie von Lebermetastasen bei kolorektalem Primärtumor (2009) (2)
- Therapie primär nichtresektabler Lebermetastasen (2008) (2)
- Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial (2019) (2)
- Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis (2022) (2)
- Assessing the role of combination therapy in mCRC (2008) (2)
- Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO group. (2010) (2)
- [Specific treatment situations in metastatic colorectal cancer]. (2010) (2)
- An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves (2022) (2)
- Oxaliplatin for colorectal cancer: recent evidence from clinical trials (2013) (2)
- Antiangiogenic Tyrosine Kinase Inhibition: How Do We Optimize Treatment for Metastatic Colorectal Cancer? (2013) (2)
- Operative und perioperative Therapie von Lebermetastasen (2008) (2)
- 93 TiPPatient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma (2017) (2)
- Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. (2014) (2)
- Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients (2022) (2)
- Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. (2020) (2)
- O-0020 Bevacizumab + Chemotherapy Beyond First Progression in Metastatic Colorectal Cancer Patients Previously Treated with Bevacizumab-Based Therapy: TML Study Subgroup Findings (2012) (2)
- Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study (2022) (2)
- Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. (2016) (2)
- REDEFINING LATER-LINE THERAPY IN METASTATIC COLORECTAL CANCER This symposium took place on 29 th June 2017 as part of the 19 th World Congress on Gastrointestinal Cancer in Barcelona , Spain Chairpersons (2017) (2)
- Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Wien, 28. September - 2. Oktober 2018: Abstracts (2018) (2)
- Two-year follow-up of a phase II study on catumaxomab as part of a multimodal approach in primarily resectable gastric cancer. (2012) (1)
- SO-3 Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial (2020) (1)
- Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies. (2019) (1)
- Administration of Chemotherapy by an Arteriovenous Fistula in a Patient with Metastatic Rectal Cancer after Life-Threatening, Port Thrombosis-Associated Cava Superior Syndrome (2012) (1)
- Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial (2013) (1)
- Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT. (2022) (1)
- "Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC). (2022) (1)
- Docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy in gastro-esophageal adenocarcinoma. (Mature results of a phase II study of the Arbeitsgemeinschaft Internistische Onkologie AIO) (2010) (1)
- POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). (2020) (1)
- Causes of mortality in elderly UICC stage III colon cancer (CC) patients––Tumor‐related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry (2022) (1)
- Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study (2022) (1)
- Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study (2012) (1)
- 409P Causes of mortality in elderly UICC stage III colon cancer (CC) patients (pts.) - Tumor related death and competing risks from the Colopredict Plus (CPP) registry (2020) (1)
- 1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial (2020) (1)
- Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: Final results of the multicenter, international PERMAD trial. (2021) (1)
- Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study (2015) (1)
- Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study. (2016) (1)
- GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers. (2022) (1)
- Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer (2013) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC). (2010) (1)
- Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature (2012) (1)
- Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749) (2014) (1)
- 650 Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – interim results from the GOBLET study (2022) (1)
- Improving the disclosure of conflicts of interest in medicine. (2019) (1)
- O-0012UPDATED RESULTS OF THE RANDOMIZED PHASE 2 IMPACT TRIAL: MAINTENANCE WITH TLR-9 AGONIST MGN1703 VS PLACEBO IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC) (2013) (1)
- Treating GI cancer during the COVID-19 pandemic in Europe (2020) (1)
- Association of microsatellite instability with distinct clinical and molecular characteristics in resected colon cancer: Analysis of a platform trial of the AIO colorectal study group—Colopredict Plus. (2017) (1)
- Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial. (2020) (1)
- POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
- Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials (2016) (1)
- Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. (2023) (1)
- Adjuvant Therapy After Liver Resection for Colorectal Cancer Metastasis: What is the Evidence? (2011) (1)
- Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P). (2020) (1)
- Real-world outcomes of patients with intrahepatic cholangiocarcinoma treated with trans-arterial radioembolization: Results from the CIRSE Registry for SIR-Spheres Therapy (CIRT), a large European prospective multi-center observational study. (2021) (1)
- Maintenance treatment in metastatic colorectal cancer - Authors' reply. (2015) (1)
- Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study. (2018) (1)
- 1077TiPIMMUNOMODULATORY MAINTENANCE THERAPY WITH TLR-9 AGONIST MGN1703 IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA-THE RANDOMIZED PHASE 3 IMPALA STUDY. (2014) (1)
- Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study. (2013) (1)
- [Long-term sequelae of cancer survivors]. (2012) (1)
- [Diagnosis and treatment of liver metastases from primary colorectal tumour]. (2009) (1)
- A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial (2013) (1)
- Paclitaxel, carboplatin and etoposid (TCE) in the treatment of advanced neuroendocrine tumours (2005) (1)
- Typologie von Medienregulierungsstilen in Europa (2015) (1)
- Palliative Chemotherapie des Kolonkarzinoms (2007) (1)
- Kurativer Ansatz für metastasierte kolorektale Karzinome (2010) (1)
- Capecitabin plus Oxaliplatin verglichen mit Fluorouracil und Folinsäure als adjuvante Therapie bei Kolonkarzinom im Stadium III (2012) (1)
- Therapie des Rektumkarzinoms (2010) (1)
- Addition of the monoclonal Epidermal Growth Factor (EGF) receptor antibody cetuximab (E) to cisplatin/5-FU (CF) versus CF in 1st line Metastatic Squamous Cell Carcinoma of the esophagus (MESCC): First results of the phase II oesotux trial (2008) (0)
- Is there an association between depression, anxiety disorders and COVID-19 severity and mortality? A multicenter retrospective cohort study conducted in 50 hospitals in Germany (2022) (0)
- PG 1.01 Rectal cancer: what is the aim of multimodal therapy? (2012) (0)
- P-49 A study of first-line treatments for patients with BRAFV600E mutant metastatic colorectal cancer in a real-life setting: CAPSTAN study (2020) (0)
- PG 4.2 Can neoadjuvant chemotherapy replace radiochemotherapy (2014) (0)
- MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer (2021) (0)
- 2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer (vol 63, pg 11, 2016) (2016) (0)
- [Treatment of nonresectable liver metastases]. (2008) (0)
- OC-0384 QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04) (2019) (0)
- Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial (2013) (0)
- Cancer survivorship in Germany: Education of GPS-Why and how? (2016) (0)
- Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial. (2010) (0)
- 1061PIMPACT STUDY: A SUBGROUP OF METASTATIC COLORECTAL CANCER PATIENTS WITH VERY PROLONGED DISEASE CONTROL UNDER MAINTENANCE THERAPY WITH THE TLR-9 AGONIST MGN1703. (2014) (0)
- Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer (2018) (0)
- Guidelines are endorsed by the Japanese Society of Medical Oncology ( JSMO ) Lynch syndrome (2013) (0)
- Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group (2012) (0)
- 218 Oxaliplatin plus capecitabine in advanced biliary adenocarcinomas: a multicenter phase II trial (2003) (0)
- Cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative triple treatment for rectal cancer (CET-CAPOX-RT-Phase-I/II Study): Influence on long-term survival and relevance of biomarkers. (2012) (0)
- Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study. (2023) (0)
- New directions in the systemic treatment of GI cancer (2006) (0)
- [Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations]. (2020) (0)
- [Colorectal carcinoma--primary treatment in case of advanced metastization]. (2008) (0)
- Erratum (2018) (0)
- 520POVERALL SURVIVAL ACCORDING TO PATIENT SUBGROUPS: RESULTS FROM A POOLED ANALYSIS OF 5 OBSERVATIONAL OR PHASE IV STUDIES OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER. (2014) (0)
- Current challenges in personalized treatment for colorectal cancer (2012) (0)
- Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. (2023) (0)
- Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction (2013) (0)
- Contents Vol. 27, 2011 (2011) (0)
- Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials (2022) (0)
- Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies. (2019) (0)
- [Resectable colorectal liver metastases: pro neoadjuvant therapy - contra neoadjuvant therapy]. (2010) (0)
- Session I. Multimodal Approach to Rectal Cancer (2012) (0)
- Predictive Biomarkers and Personalized Medicine EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients (2011) (0)
- IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma. (2014) (0)
- Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer. (2022) (0)
- Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study (2016) (0)
- Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database. (2017) (0)
- Grundlagen der Immuntherapie (2020) (0)
- Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab. (2016) (0)
- Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study. (2023) (0)
- P-307Immunomodulatory switch maintenance therapy to improve overall survival in metastatic colorectal carcinoma: The phase 3 IMPALA study (2015) (0)
- [Treatment of rectal cancer]. (2010) (0)
- Predictive Biomarkers and Personalized Medicine Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (2011) (0)
- GOBLET-Studie (AIO-KRK-0320) (2021) (0)
- Treatment and Survival Outcomes by Age Following Second-Line Therapy for Metastatic CRC (mCRC): Analysis of 13,149 Patients from the ARCAD Clinical Trials Program (2021) (0)
- [ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]. (2006) (0)
- Active Maintenance Therapy Prolongs TFS and PFS in CRC (2014) (0)
- Gastric cancer (cid:2) : ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up q (2014) (0)
- 6515 POSTER Application of the Trifunctional Antibody Catumaxomab as Part of a Multimodal Approach in Resectable Gastric Cancer is Feasible and Promotes the Development of Tumour-specific Immune Responses (2011) (0)
- Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice (2022) (0)
- PD-0025DISEASE PROGRESSION PATTERNS/OUTCOME BY DISEASE EXTENT FOLLOWING BEVACIZUMAB + CHEMOTHERAPY BEYOND FIRST DISEASE PROGRESSION IN PREVIOUSLY TREATED MCRC (ML18147 STUDY) (2013) (0)
- Meetings and Conferences · Tagungen und Kongresse (2001) (0)
- European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer. (2023) (0)
- Should bevacizumab be continued beyond progression in colorectal cancer? (2008) (0)
- OC-0499 Neutrophilia as prognostic factor for outcome in the CAO/ARO/AIO-04 phase 3 rectal cancer trial (2019) (0)
- Effect of pathohistologic complete remission (pCR) rate on the prediction of long-term prognosis following chemoradiotherapy (XRT) with cetuximab (Cet), capecitabine (CAP), and oxaliplatin (OX; Cet-CAPOX) in patients (pts) with locally advanced rectal cancer (LARC). (2011) (0)
- 2141 Safety outcomes from 3 observational or phase 4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC) (2015) (0)
- PD-0009A SUBGROUP OF METASTATIC COLORECTAL CANCER PATIENTS WITH VERY PROLONGED DISEASE CONTROL UNDER MAINTENANCE THERAPY WITH THE TLR-9 AGONIST MGN1703 (2014) (0)
- P-51 Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients (2021) (0)
- Rolf Stahel & Dirk Arnold: Trends in Lung Cancer Treatment and Key Roles of Comprehensive Cancer Centers (2018) (0)
- Catumaxomab as part of a multimodal approach in primarily resectable gastric cancer: 2-year follow-up of a phase II study (2012) (0)
- Abstract B61: Exploratory analyses of the randomized phase 2 IMPACT study: Patients with response to prior induction chemotherapy have improved outcome when treated with the TLR-9 agonist MGN1703 (2015) (0)
- A Breath of Fresh Air at the End of Summer: And Some Thoughts About New Structures in Cancer Medicine (2018) (0)
- Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries (2022) (0)
- A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. (2018) (0)
- 1487PDINTRAPERITONEAL BEVACIZUMAB (BEV) FOR CONTROL OF MALIGNANT ASCITES DUE TO ADVANCED-STAGE GASTROINTESTINAL CANCERS (GI): A MULTICENTER DOUBLE-BLIND, PLACEBO (PL)-CONTROLLED, RANDOMIZED PHASE II STUDY. AIO SUP-0108. (2014) (0)
- 111P Real-world outcomes of patients with breast cancer liver metastases treated with transarterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study (2021) (0)
- Adjuvante Therapie des Kolonkarzinoms (2009) (0)
- Supportive care. (1992) (0)
- Europäische Antworten auf die Ressourcenkrise des Journalismus (2017) (0)
- Correlation of psychosocial factors (PSF) before and throughout treatment with response to chemotherapy (CTx) in patients (pts) with advanced gastrointestinal (GI) cancers: Does psychosocial status predict tumor remission? (2013) (0)
- Pursuing the NED condition in stage IV colorectal cancer (2012) (0)
- Reply to O. Gires et al (2010) (0)
- Editorial Board / Contents / Imprint (2016) (0)
- Multizentrische Phase II Studie mit Oxaliplatin plus Capecitabin bei fortgeschrittenen biliären Adenokarzinomen (2015) (0)
- Kombinationstherapie mit Gemcitabine, 5-FU und Folinsäure bei inoperablem Pankreaskarzinom, eine klinische Phase-II-Studie (2000) (0)
- Stellenwert und qualitative Voraussetzungen der Magnetresonanztomographie für die Therapieplanung beim lokal fortgeschrittenen Rektumkarzinom – interdisziplinäre Empfehlungen (2020) (0)
- Konsensusempfehlungen deutscher Experten - Management der Therapie mit Idelalisib (2017) (0)
- Berghofer, Simon: Globale Medien- und Kommunikationspolitik. Konzeption und Analyse eines Politikbereichs im Wandel (2018) (0)
- Das Konzept Mediensystem in Zeiten von Konvergenz und Digitalisierung - Call for Papers zum Workshop 2018 (2018) (0)
- 2. ITLT Essen 2011 - Interdisziplinäre Therapie von Lebertumoren (2011) (0)
- Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group. (2022) (0)
- Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up (2014) (0)
- Patterns of maintenance treatment (Tx) following first-line bevacizumab (bev) plus chemotherapy (CT) for metastatic colorectal cancer (mCRC): Results from a large German community-based cohort study. (2011) (0)
- Peritonealkarzinose bei gastrointestinalen Malignomen : Fortschritte durch multimodale Therapie (TOPIC 2 · peritonealkarzinose) (2009) (0)
- Eine Gesellschaft der Methusaleme: Herausforderung und Chance? Ist der Fortschritt in der Medizin noch bezahlbar? (2008) (0)
- CRS und HIPEC als additive Therapieoptionen mit peritoneal metastasiertem Kolon- und Appendixkarzinom – die COMBATAC-Studie (2011) (0)
- Schmitt, Martin: Internet im Kalten Krieg. Eine Vorgeschichte des globalen Kommunikationsnetzes (2017) (0)
- Assessing outcome differences in the second line treatment of metastatic colorectal cancer (mCRC): An ARCAD analysis comparing sequence after first line trials (SAFL) and dedicated second line trials (DSLT). (2017) (0)
- Resektable Lebermetastasen beim kolorektalen Karzinom: pro neoadjuvante Therapie -contra neoadjuvante Therapie (2010) (0)
- Medienpolitik in hybriden Mediensystemen (2020) (0)
- Intramuskuläre Metastasen: Prevalenz, Lokalisation, klinische und radiologische Zeichen (2010) (0)
- Erste DGHO-Frühjahrstagung in Berlin: Brückenschlag zwischen Versorgung, Wissenschaft und Politik (2008) (0)
- Grundlegende Erkenntnisse zur Elektrostimulation des M triceps brachii von Rattus norvegicus. (2011) (0)
- Berghofer, Simon: Globale Medien- und Kommunikationspolitik. Konzeption und Analyse eines Politikbereichs im Wandel (2018) (0)
- Zwei Therapieschemata im Vergleich (2012) (0)
- Sequential or combination chemotherapy for a patient with mCRC? (2008) (0)
- Kolorektales Karzinom – Primärtherapie bei fortgeschrittener Metastasierung (2008) (0)
- 53/m mit bewegungsabhängigen Schmerzen im linken vorderen Becken und blutigem Urin (2022) (0)
- Label-free and automated approach to rapidly classify microsatellite instability (MSI) in early colon cancer (CC) analyzing the AIO ColoPredictPlus 2.0 (CPP) registry trial. (2022) (0)
- Palliative und supportive Therapie beim Karzinom des ösophagogastralen Übergangs (2012) (0)
- Das Vertrauensdilemma im Verhältnis zwischen Medien-PR und Medienjournalismus (2018) (0)
- Medienföderalismus: Geschichte der Auslöser und Auswege für Kompetenzstreite (2018) (0)
- Nervenverletzungen durch die Verwendung intramuskulärer Mehrkanalelektroden (2011) (0)
- Title Pages / 11. Interdisziplinärer Expertenworkshop Gastrointestinale Tumore / Table of Contents (2011) (0)
- Pflege als Frauenberuf im Krankenhaus – die Verkörperung des Widerspruchs zwischen „Arbeit“ und Zuwendung (2012) (0)
- Regulierung der Social Media: Rechte und Pflichten neuer Anbietertypen im europäischen Vergleich (2019) (0)
- Schmitt, Martin: Internet im Kalten Krieg. Eine Vorgeschichte des globalen Kommunikationsnetzes (2017) (0)
- Vorspann (1997) (0)
- Untersuchung zu Determinanten der Inzidenz von Katheterkomplikationen bei heim-parenteraler Ernährung: Planung, Ablauf und statistische Methodenansätze (2007) (0)
- VIII. Interdisziplinärer Expertenworkshop 2008 ‘Gastrointestinale Tumore’ – Autorenverzeichnis (2008) (0)
- Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT). (2013) (0)
- Sektorenübergreifende Begleitung nach Krebs: Ziel ist frühe Diagnose eines potenziell heilbaren Rezidivs (2015) (0)
- Was wir brauchen, ist mehr Wissen! (2001) (0)
- Dichtungsanordnung für ein bewegliches Dachelement in einem Kraftfahrzeug (2000) (0)
- Lymphom der Skelettmuskulatur. Häufigkeit, Klinische Zeichen und Radiologische Manifestation (2009) (0)
- [Adjuvant therapy of pancreatic carcinoma]. (2000) (0)
- Sequenztherapie beim fortgeschrittenen Nierenzellkarzinom (2010) (0)
- Peritonealkarzinose bei gastrointestinalen Malignomen (2009) (0)
- [Surgical and perioperative therapy of liver metastases]. (2008) (0)
- Inhalt Band 27, 2011 (2011) (0)
- Arbeitsgruppen zu kolorektalen Tumoren der AIO, der ACO und der ARO – „past, present, and future“ (2022) (0)
- 3PC-041 Surface contamination with cytotoxic drugs in European hospital wards (2020) (0)
- [Basic principles of immunotherapy]. (2020) (0)
- Title Pages / Table of Contents (2012) (0)
- PD-0030 2-Year Follow-Up of A Phase II Study on Catumaxomab as Part of a Multimodal Approach in Primarily Resectable Gastric Cancer (2012) (0)
- Prognostic factors for long-term overall survival (OS) for patients (pts) undergoing first-line treatment for metastatic colorectal cancer (mCRC) with chemotherapy (CT) plus bevacizumab (bev): Findings from a large observational study. (2012) (0)
- Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results (2014) (0)
- 422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs) (2020) (0)
- Syddansk Universitet Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma ( ACTICCA-1 trial )-a randomized , multidisciplinary , multinational phase III trial (2015) (0)
- Palliative Therapie des kolorektalen Karzinoms (2009) (0)
- Multimodale Therapie des lokalisierten Magenkarzinoms (2016) (0)
- Severe Nonbacterial Thrombotic Endocarditis Resulting in Aortic Valve Insufficiency and Multiple Small Strokes in a Patient With Metastatic Pancreatic Cancer: Lessons for Optimal Management. (2020) (0)
- Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study (Preprint) (2019) (0)
- 2089 Response to chemotherapy allows to identify mCRC patients most likely to benefit from maintenance immunotherapy: A post-hoc analysis from the IMPACT study (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Dirk Arnold?
Dirk Arnold is affiliated with the following schools:
